Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40RA6 | ISIN: US6979471090 | Ticker-Symbol: PI6
München
06.06.25 | 08:00
21,000 Euro
-2,78 % -0,600
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALVELLA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PALVELLA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PALVELLA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Palvella Therapeutics ernennt Ashley Kline zur Chief Commercial Officer1
27.05.Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer3
15.05.Palvella Therapeutics Q1 2025 slides: pipeline advances with strong cash position4
15.05.Palvella Therapeutics GAAP EPS of -$0.741
15.05.PALVELLA THERAPEUTICS, INC. - 10-Q, Quarterly Report1
15.05.Palvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update160Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40...
► Artikel lesen
15.05.PALVELLA THERAPEUTICS, INC. - 8-K, Current Report1
05.05.Palvella Therapeutics Inc.: Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 20255
PALVELLA THERAPEUTICS Aktie jetzt für 0€ handeln
30.04.Why Palvella Therapeutics, Inc. (PVLA) is Surging in 20251
23.04.Palvella Therapeutics Inc.: Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of ...2
22.04.Palvella Therapeutics secures new patent for rare skin disease gel4
22.04.Palvella Therapeutics Inc.: Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations93Fifth issued patent in the U.S. for QTORIN rapamycin with anticipated patent life extending into 2038 QTORIN rapamycin has the potential to be the first approved therapy and standard of care for microcystic...
► Artikel lesen
11.04.Palvella Therapeutics Inc.: Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology ...183Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and...
► Artikel lesen
09.04.Chardan sets $50 target on Palvella Therapeutics stock1
31.03.Stifel maintains $45 target on Palvella Therapeutics stock4
31.03.Palvella Therapeutics GAAP EPS of -$7.833
31.03.Palvella Therapeutics, Inc. Full Year Earnings Summary2
31.03.PALVELLA THERAPEUTICS, INC. - 10-K, Annual Report-
31.03.Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update116Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical...
► Artikel lesen
31.03.PALVELLA THERAPEUTICS, INC. - 8-K, Current Report1
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1